Biogen Inc. CEDEAR (BIIB)
BCBA
27,540.00
-100.00 (-0.36%)
Closed
Oct 7, 2026
Day's Range
27,520.0028,120.00
52 wk Range
15,000.0028,740.00
Financial Statements - BIIB - Biogen Inc. CEDEAR
Revenue
9.89B▼ 99.9%
Net Income
1.29B▼ 99.9%Net Margin 13.1%
EBITDA
3.39B▼ 99.9%
Free Cash Flow
1.96B▼ 99.9%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 9.89B | 13.91T | 10.38T | 10.74T | 11.59T | 14.19T |
| Cost of Goods | 2.40B | 3.32T | 2.67T | 2.40T | 2.22T | 1.90T |
| Gross Profit | 7.48B | 10.59T | 7.70T | 8.33T | 9.36T | 12.29T |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 2.46B | 3.19T | 1.93T | 3.06T | 2.96T | 4.69T |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -770M | -187.26B | -595.26B | 894.63B | -866.12B | 825.47B |
| Pre Tax Income | 1.55B | 2.74T | 1.36T | 3.79T | 1.84T | 5.33T |
| Income Tax | 263.60M | 393.79B | 142.82B | 668.23B | 55.43B | 1.04T |
| Net Income | 1.29B | 2.34T | 1.22T | 3.12T | 1.82T | 4.28T |
| EPS Basic | 8.83 | 11.21 | 8.02 | 20.96 | 10.44 | 24.86 |
| EPS Diluted | 8.79 | 11.18 | 7.97 | 20.87 | 10.4 | 24.8 |
| Basic Shares Outstanding | 146.50M | 209.40B | 144.70M | 145.30M | 149.10M | 160.90M |
| Diluted Shares Outstanding | 146.50M | 209.40B | 144.70M | 145.30M | 149.10M | 160.90M |
| Ebit | 1.82B | 3.10T | 1.62T | 4.05T | 2.11T | 5.56T |
| Ebitda | 3.39B | 4.34T | 2.74T | 3.69T | 3.90T | 5.23T |
| Net Income Continuous Operations | 1.29B | 2.34T | 1.22T | 3.12T | 1.82T | 4.28T |
| Minority Interests | 0 | 0 | -400K | 85.30M | -171.50M | -59.90M |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
